$CLLS

$1.05 +$0.08 (8.64%) Close

$CLLS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 71.8M shares outstanding

Who owns CLLS?

By type of holder

Institutions 13.1% Everyone else 86.9%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 87.7%

AstraZeneca PLC 61.3% · Bpifrance Participations S.A. 13.3%

Institutional ownership

13.1%

-1.1 pts vs last qtr

Institutional holders

-6 vs last qtr

Net shares bought

−817.9K

by institutions in Q2 2026

New / sold out

3 / 9

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

UBS Group AG +4.2K
Royal Bank Of Canada NEW +1.6K

Biggest sellers in Q2 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC −533.7K
BlackRock, Inc. −116.1K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Cellectis SA in the last 12 months.

Is your stake being diluted?

There are not yet two fiscal years of reported share counts for Cellectis SA.

How patient are the owners?

Institutional shares by how long they've been held

5+ years1% 3–5 years31% 1–3 years35% Under 1 year33%

Quarterly turnover

4.0%

of institutional shares changed hands

Top 10 managers, median time held

1.5 years

Super Investors

Investment managers reporting CLLS on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
BG B Group, Inc.	3.3M	4.57%	Unchanged	2024	4.6%
Shares held by quarter Peak holding3.3M (Q3'25) Change over 8 quarters+3.3M Share of the company4.570% B Group, Inc.'s full portfolio →
UA UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	2.6M	3.69%	−533.7K (−16.8%)	Q4 '25	0.0%
Shares held by quarter Peak holding4.7M (Q1'25) Change over 8 quarters+1.2M Share of the company3.690% UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's full portfolio →

B Group, Inc.

3.3M

% of company

4.57%

Change vs last qtr

Unchanged

Held since

2024

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

2.6M

% of company

3.69%

Change vs last qtr

−533.7K (−16.8%)

Held since

Q4 '25

28 more super investors behind a free account

See every manager holding Cellectis SA, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting CLLS on Form N-PORT; together they hold 0.6% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
NH Nomura Healthcare Fund Delaware Group Equity Funds IV	$681K	226.9K	0.32%	0.09%	June 30, 2026
IB iShares Biotechnology ETF iShares Trust	$669K	223.1K	0.31%	0.01%	June 30, 2026

Nomura Healthcare Fund

Delaware Group Equity Funds IV

Position value

$681K

% of company

0.32%

% of the fund

0.09%

As of

June 30, 2026

iShares Biotechnology ETF

iShares Trust

Position value

$669K

% of company

0.31%

% of the fund

0.01%

As of

June 30, 2026

1 more funds behind a free account

See every fund holding Cellectis SA and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
AP AstraZeneca PLC 5%+ holder 13D · 44.0%	44.0M	61.32%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company61.320% Disclosed stake13D · 44.0% View the 13D/G filing →
BP Bpifrance Participations S.A. 5%+ holder 13D · 10.0%	9.6M	13.32%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company13.320% Disclosed stake13D · 10.0% View the 13D/G filing →

AstraZeneca PLC

5%+ holder13D · 44.0%

44.0M

% of company

61.32%

Change vs last qtr

—

Held since

—

Bpifrance Participations S.A.

5%+ holder13D · 10.0%

9.6M

% of company

13.32%

Change vs last qtr

—

Held since

—

Comments